UNSPSC 51111650: Pemetrexed

This classification denotes a thymidylate synthase inhibitor and folate antagonist with the molecular formula C20H21N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04Q9AIZ7NO, chemically known as n-(4-(2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid but generally known as pemetrexed, which bears US NIH Compound Identifier 60843. European Medicines Agency schedules Pemetrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09655MIG.

UNSPSC 51111650 Pemetrexed, a Commodity code, covers the procurement of pemetrexed, a chemotherapy drug used primarily to treat mesothelioma and certain forms of non-small-cell lung cancer. State and local governments acquire pemetrexed through their health departments, public hospital systems, correctional health programs, and purchasing consortia that serve multiple agencies. The drug is typically procured as part of broader oncology or pharmaceutical inventory contracts, often bundled with related chemotherapy agents or acquired through state Medicaid programs and public health clinics that serve uninsured or underinsured populations.

The source provided contains no recent state or local contract opportunities under this code and does not identify issuing bodies, geographic activity, or representative solicitations.